BridgeBio Oncology Therapeutics Inc. (BBOT) Financial Analysis & Valuation | Quarter Chart
BridgeBio Oncology Therapeutics Inc. (BBOT)
BBOTPrice: $11.53
Fair Value: 🔒
🔒score
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors. Initially formed as a subsidiary of BridgeBio Pharma, it focuses on precision onco... more
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-genera... more
Description
Shares
| Market Cap | $922.27M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Eli Wallace |
| IPO Date | 2025-08-12 | CAGR | — |
| Employees | 62 | Website | — |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
BBOT chart loading...
Fundamentals
Technicals
| Enterprise Value | $-133.62M | P/E Ratio | -11.05 |
| Forward P/E | -4.48 | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 0.61 |
| P/CF Ratio | -2.86 | P/FCF Ratio | -9.66 |
| EPS | $-1.1 | EPS Growth 1Y | -839.87% |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | — | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | -0.77% | ROA | -0.24% |
| ROCE | -0.28% | Current Ratio | 13.33 |
| Quick Ratio | 13.33 | Cash Ratio | 11.45 |
| Debt/Equity | 0.01 | Interest Coverage | — |
| Altman Z Score | 12.96 | Piotroski Score | 1 |
View BridgeBio Oncology Therapeutics Inc. financial charts →